Trial Profile
A Randomized, Double-blind, Placebo Controlled Trial of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in High-risk Adults in the Critical Care Setting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Caspofungin (Primary)
- Indications Candidaemia; Invasive candidiasis
- Focus Therapeutic Use
- 15 Apr 2014 New trial record
- 18 Feb 2014 Primary endpoint 'Infection-rate' has not been met.
- 18 Feb 2014 Results published in the Clinical Infectious Diseases.